Related Experiment Video
Updated: Jul 3, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Dehydroepiandrosterone in systemic lupus erythematosus
1amr-sawalha@omrf.ouhsc.edu
Current Rheumatology Reports
|July 30, 2008
Summary
Dehydroepiandrosterone (DHEA) supplementation may improve quality of life in lupus patients but its effect on disease activity is debated. Further safety studies are needed due to potential impacts on cholesterol levels.
Area of Science:
- Immunology
- Endocrinology
- Rheumatology
Background:
- Dehydroepiandrosterone (DHEA) is a hormone with complex immune effects, but its mechanism of action is unclear.
- Lower DHEA levels correlate with increased disease activity in inflammatory conditions like lupus.
- Preclinical studies suggest DHEA may benefit lupus models.
Purpose of the Study:
- To evaluate the efficacy and safety of DHEA supplementation in lupus patients.
- To investigate DHEA's impact on disease activity, quality of life, and glucocorticoid use.
Main Methods:
- Clinical studies involving DHEA supplementation in patients with lupus.
- Assessment of disease activity, quality-of-life measures, and glucocorticoid requirements.
- Monitoring of safety parameters, including lipid profiles.
Main Results:
- DHEA treatment showed potential to improve quality of life and reduce steroid needs in some lupus patients.
- The effect of DHEA on overall lupus disease activity remains controversial.
- Concerns exist regarding DHEA's impact on high-density lipoprotein cholesterol levels.
Conclusions:
- DHEA may offer benefits for mild to moderate lupus, particularly in quality of life and steroid reduction.
- More research is needed to clarify DHEA's role in lupus management and its long-term safety profile.
- The controversial impact on disease activity and lipid profiles warrants careful consideration.